Patient with high titer acquired FVIII inhibitor with no causative etiology. Bleeding is well-controlled on emicizumab, but inhibitor has failed to respond to corticosteroids, rituximab, cyclophosphamide, and mycophenolate. With bleeding controlled, she is now developing more problems from immunosuppressive therapy than from the inhibitor.